- Celldex ends skin disease program after failing phase 2 testA phase 2 study of Celldex’s barzolvolimab in a chronic skin disease has missed its primary endpoint, driving the biotech to end development in the indication and raising doubts about an upcoming e…Fierce Biotech · 5d ago↗ source
- AI data becomes sticking point in biopharma dealmakingAs drug hunting gets more complex, where and how data is generated in partnerships between Big Pharmas and AI biotechs is becoming a headache for dealmakers.BioSpace · 5d ago↗ source
- STAT+: More workers hate their jobs, but keep them for the health insuranceA new survey reveals 24% of U.S. workers stay in unwanted jobs to keep health insurance. Experts call it 'job lock.'STAT · 5d ago